Abstract:Abstract Context As living standards have improved and lifestyles have undergone changes, metabolic diseases associated with obesity have become increasingly prevalent. It is well established that sesamin (Ses) (PubChem CID: 72307), the primary lignans in sesame seeds and sesame oil, possess antioxidant and anti-inflammatory effects. Objective In this study, a systematic review and meta-analysis of the effects of Ses on animal models of obesity-related diseases was performed to assess their impact on relevant disease parameters. Importantly, this study sought to provide insights for the design of future human clinical studies utilizing Ses as a nutritional supplement or drug. Data Sources This study conducted a comprehensive search in PubMed, Web of Science, Embase, Scopus, and the Cochrane Library, identifying English language articles published from inception to April 2023. Data Extraction The search incorporated keywords such as “sesamin,” “obesity,” “non-alcoholic fatty liver disease,” “type 2 diabetes mellitus,” and “metabolic syndrome.” The meta-analysis included 17 articles on non-alcoholic fatty liver disease, type 2 diabetes, and metabolic syndrome. Data Analysis Overall, the pooled results demonstrated that Ses significantly reduced levels of total serum cholesterol (P = .010), total serum triglycerides (P = .003), alanine transaminase (P = .003), and blood glucose (P < .001), and increased high-density lipoprotein cholesterol levels (P = .012) in animal models of nonalcoholic fatty liver disease. In the type 2 diabetes model, Ses mitigated drug-induced weight loss (P < .001), high-fat-diet–induced weight gain (P < .001), and blood glucose levels (P = .001). In the metabolic syndrome model, Ses was associated with a significant reduction in body weight (P < .001), total serum cholesterol (P < .001), total serum triglycerides (P < .001), blood glucose (P < .001), and alanine transaminase levels (P = .039). Conclusion The meta-analysis results of this study suggest that Ses supplementation yields favorable effects in animal models of obesity-related diseases, including hypolipidemic, insulin-lowering, and hypoglycemic abilities, as well as organ protection from oxidative stress and reduced inflammation. Systematic Review Registration PROSPERO registration No. CRD42023438502.

Sesamolin Attenuates Kidney Injury, Intestinal Barrier Dysfunction, and Gut Microbiota Imbalance in High-Fat and High-Fructose Diet-Fed Mice

Sesamolin Alleviates Nonalcoholic Fatty Liver Disease Through Modulating Gut Microbiota and Metabolites in High-Fat and High-Fructose Diet-Fed Mice

Sesamin Ameliorates High-Fat Diet-Induced Dyslipidemia And Kidney Injury By Reducing Oxidative Stress

Sesamol Supplementation Attenuates DSS-Induced Colitis Via Mediating Gut Barrier Integrity, Inflammatory Responses, and Reshaping Gut Microbiome

Sesamin Attenuates Obesity-Associated Nonalcoholic Steatohepatitis in High-Fat and High-Fructose Diet-Fed Mice.

Sesamol ameliorates high-fat and high-fructose induced cognitive defects via improving insulin signaling disruption in the central nervous system.

Sesamol Counteracts on Metabolic Disorders of Middle-Aged Alimentary Obese Mice Through Regulating Skeletal Muscle Glucose and Lipid Metabolism

Protective Effects of Sesamol on Renal Ischemia-Reperfusion Injury Via Regulation of Nuclear Factor Erythroid 2-Related Factor 2 Pathway

Sesamin Protects Against Dss-Induced Colitis In Mice By Inhibiting Nf-Kappa B And Mapk Signaling Pathways

Preventive Effects of Sesamol on Deep-Frying Oil-Induced Liver Metabolism Disorders by Altering Gut Microbiota and Protecting Gut Barrier Integrity.

Protective effect of sesamin in lipopolysaccharide-induced mouse model of acute kidney injury via attenuation of oxidative stress, inflammation, and apoptosis

Protective Effects of Sesamol against Liver Oxidative Stress and Inflammation in High-Fat Diet-Induced Hepatic Steatosis

Sesamol Ameliorates Diet-Induced Obesity in C57BL/6J Mice and Suppresses Adipogenesis in 3T3-L1 Cells Via Regulating Mitochondria-Lipid Metabolism.

Sesamol supplementation alleviates nonalcoholic steatohepatitis and atherosclerosis in high-fat, high carbohydrate and high-cholesterol diet-fed rats

Sesamin Protects against and Ameliorates Rat Intestinal Ischemia/Reperfusion Injury with Involvement of Activating Nrf2/HO-1/NQO1 Signaling Pathway

Protective effects of sesamin on liver fibrosis through antioxidative and anti-inflammatory activities in rats

Sesamin Ameliorates Hepatic Steatosis and Inflammation in Rats on A High-Fat Diet Via Lxr Alpha and Ppar Alpha

Effects of Sesamin in Animal Models of Obesity-Associated Diseases: A Systematic Review and Meta-Analysis

Sesamol intervention ameliorates obesity-associated metabolic disorders by regulating hepatic lipid metabolism in high-fat diet-induced obese mice

The ApoE-dependent Neuroprotective Effects of Sesamol on Diet-induced Obese Mice: the Role of Gut Microbiota and SCFAs (P06-049-19).

ApoE-Dependent Protective Effects of Sesamol on High-Fat Diet-Induced Behavioral Disorders: Regulation of the Microbiome-Gut-Brain Axis.